Australian Technical Advisory Group on Immunisation: In the context of a Covid-19 outbreak where the supply of Comirnaty (Pfizer) is constrained, adults younger than 60 years old, who do not have immediate access to Comirnaty (Pfizer), should reassess the benefits to them and their contacts from being vaccinated with Covid-19 vaccine AstraZeneca, versus the rare risk of a serious side effect.

Recap of ATAGI's 'evolving' advice re AZ in recent months:

1. Recommended for all ages - 3 mths btw shots
2. Rec for over-50's only
3. Rec for over-60's only
4. Rec for all ages - 2 mths btw shots

Interesting to see the Pfizer rebranding. Pfizer is a company, the vaccine being one of thousands of drugs they produce, so it's normal to have a brand name - but curious why it comes now?

'Comirnaty'? Weird name - sounds too similar to 'Communist Party'.

Whatever, the outlook is rosy - the company raised its forecast estimate for 2021 profits from the jab by 70% - to a cool 26 bil. Then it keeps rolling in from there...

Albert Bourla, Chief Executive: Based on what we've seen, we believe that a durable demand for our COVID-19 vaccine – similar to that of the flu vaccines – is a likely outcome.